Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we examined the effect of empagliflozin (Empa) on the ultrastructure of cardiomyocytes in the noninfarcted region of the diabetic heart after myocardial infarction (MI). OLETF, a rat model of type 2 diabetes,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Physiol Rep
Autors principals: Mizuno, Masashi, Kuno, Atsushi, Yano, Toshiyuki, Miki, Takayuki, Oshima, Hiroto, Sato, Tatsuya, Nakata, Kei, Kimura, Yukishige, Tanno, Masaya, Miura, Tetsuji
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014462/
https://ncbi.nlm.nih.gov/pubmed/29932506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14814/phy2.13741
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars